Home » Stocks » CRIS

Curis, Inc. (CRIS)

Stock Price: $7.61 USD -0.46 (-5.70%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
Pre-market: $7.60 -0.01 (-0.13%) Jun 16, 9:00 AM
Market Cap 738.69M
Revenue (ttm) 10.32M
Net Income (ttm) -30.13M
Shares Out 91.51M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $7.61
Previous Close $8.07
Change ($) -0.46
Change (%) -5.70%
Day's Open 8.01
Day's Range 7.57 - 8.05
Day's Volume 4,576,514
52-Week Range 0.90 - 17.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS).  Such investors are advised to contact Robe...

4 hours ago - PRNewsWire

The company will bring a lower dose of an important pipeline drug into a phase 2 clinical trial.

4 days ago - The Motley Fool

Curis Inc (NASDAQ: CRIS) has announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Key findings w...

4 days ago - Benzinga

LEXINGTON, Mass., June 11, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced upd...

5 days ago - PRNewsWire

LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

1 week ago - PRNewsWire

LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the ...

2 weeks ago - PRNewsWire

LEXINGTON, Mass., May 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

3 weeks ago - PRNewsWire

AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021

Other stocks mentioned: AXDX, FSTR, GO, PRLB
3 weeks ago - Zacks Investment Research

The swoon came shortly after some very good news for the company.

1 month ago - The Motley Fool

Curis Inc (NASDAQ: CRIS) stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndro...

1 month ago - Benzinga

LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...

1 month ago - PRNewsWire

Curis Inc (NASDAQ: CRIS) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk mye...

1 month ago - Benzinga

LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

1 month ago - PRNewsWire

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

LEXINGTON, Mass., May 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that ...

1 month ago - PRNewsWire

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to anno...

1 month ago - PRNewsWire

LEXINGTON, Mass., April 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

2 months ago - PRNewsWire

LEXINGTON, Mass., April 6, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

2 months ago - PRNewsWire

Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-Ti...

Other stocks mentioned: AMD, FB, GOOGL, MSFT, RXDX, V
2 months ago - GuruFocus

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Other stocks mentioned: PDD, SRGA
2 months ago - Benzinga

Shares of Curis (NASDAQ:CRIS) decreased after the company reported Q4 results. Quarterly Results Earnings per share increased 57.69% year over year to ($0.11), which missed the estimate of ($0.09).

2 months ago - Benzinga

LEXINGTON, Mass., March 16, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its...

2 months ago - PRNewsWire

LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th...

3 months ago - PRNewsWire

LEXINGTON, Mass., March 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

3 months ago - PRNewsWire

LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

3 months ago - PRNewsWire

Quick overview of Curis and stock price history. Review on the potential for therapies that target the immune system checkpoint regulator “VISTA” (V-domain immunoglobulin (Ig) suppressor of T cell activ...

4 months ago - Seeking Alpha

LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

5 months ago - PRNewsWire

Overview of Curis, including key partnerships, balance sheet, and recent stock price. Review of Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes and Acute Myeloid Leukemia. Patient need, current key th...

5 months ago - Seeking Alpha

Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)

Other stocks mentioned: BLNK
6 months ago - OTC PR Wire

Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Curis Inc. (NASDAQ: CRIS) shares are on the run again.

6 months ago - 24/7 Wall Street

LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the p...

6 months ago - PRNewsWire

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up ...

6 months ago - Zacks Investment Research

The stock price of Curis, Inc. (NASDAQ: CRIS) increased by 354.86% as it went from a previous close of $1.44 to $6.55 per share today. This is why it happened.

6 months ago - Pulse2

Curis, Inc. staged an eye-popping rally on Tuesday after it released positive preliminary data related to its phase one trial of CA-4948, a small molecule inhibitor that is being tested in patients with...

6 months ago - Business Insider

Further gains for the top stock market came from big movers.

Other stocks mentioned: SFIX
6 months ago - The Motley Fool

Curis, Inc. (NASDAQ: CRIS) shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myeloid leukem...

6 months ago - Benzinga

Curis (CRIS) stock is taking off on Tuesday following news of positive preliminary data from a Phase 1 clinical trial for its leukemia drug. The post CRIS Stock News: Why Biotech Stock Play Curis Is Goi...

6 months ago - InvestorPlace

After Curis Inc. (NASDAQ: CRIS) announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), its shares absol...

6 months ago - 24/7 Wall Street

Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study of its le...

6 months ago - Market Watch

LEXINGTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced upda...

6 months ago - PRNewsWire

Curis, Inc. (CRIS) CEO Jim Dentzer on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Curis, Inc. (CRIS) CEO Jim Dentzer On Q3 2020 Results - Quick Version Earnings Call Transcript

7 months ago - Seeking Alpha

Shares of Curis (NASDAQ:CRIS) fell 0.88% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 42.11% year over year to ($0.11), which beat the es...

7 months ago - Benzinga

LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

7 months ago - PRNewsWire

LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

7 months ago - PRNewsWire

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a...

7 months ago - PRNewsWire

LEXINGTON, Mass., Oct. 14, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

8 months ago - PRNewsWire

Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 1, 2000
CEO
James Dentzer
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
CRIS
Full Company Profile

Financial Performance

In 2020, Curis, Inc.'s revenue was $10.84 million, an increase of 8.31% compared to the previous year's $10.00 million. Losses were -$29.91 million, -6.95% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Curis, Inc. stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 202.23% from the latest price.

Price Target
$23.00
(202.23% upside)
Analyst Consensus: Buy